The U.S. government’s vaccine campaign against the coronavirus, known as COVID-19, has begun to hit the U.K. and other nations where COVID is spreading.
But a new study shows that people in Europe and North America can’t shed the virus without the vaccine.
In the study, published online today in the American Journal of Public Health, researchers looked at data from more than 20 million people between April and June 2015.
Researchers found that the people who were vaccinated had higher levels of antibody to COVID than those who weren’t vaccinated.
“When we looked at people who had received the vaccine, their antibodies went up significantly,” said study lead author John Osterholm, a professor of epidemiology at the University of Southern California.
“In other words, the vaccine made antibodies that were more effective at killing the virus.”
Osterholm and his colleagues used a computer algorithm to measure the number of antibodies to COVEc and other viruses, and they were surprised to find that people who received the vaccination had more antibodies than those not vaccinated.
They also found that people vaccinated had the antibodies in their blood more often.
“People who were vaccinating were much more likely to be antibody-positive, even though they didn’t have antibodies in the blood,” Osterheim said.
This suggests that the antibodies that people get in their body are a sign of a vaccine, rather than an indication that they are infected.
“There’s no indication that people are shedding the virus,” he said.
In a second study, the researchers compared the antibodies to a control group that was not vaccinated, and found that antibodies to all viruses were higher in people who weren.
“Our results suggest that the vaccine actually makes antibodies that are more effective in killing the coronovirus,” Oesterholm said.
“So, the vaccination actually makes you more susceptible to getting the coronowith the vaccine.”
There are two kinds of antibodies in humans.
There’s the immune system’s own response to an infection, called an antibody response, and there’s the circulating antibody response that’s produced by the immune systems to foreign objects, such as viruses.
Osterheim thinks the antibodies are produced by a third type of antibody called non-specific antigen.
Non-specific antibodies are antibodies that don’t attack anything, but that do react with some foreign antigen.
“We think that non-selective antibodies are the ones that are really important because they’re involved in making antibodies,” Oterholm said, “but we don’t know if they are the one that makes antibodies to coronaviruses.”
Oesterholm’s team analyzed antibodies in people vaccinated against the virus to find out whether non-responsive people have antibodies that can’t be detected by the body’s own immune system.
They found that this was the case.
“It’s not like if you get a tick, you can’t get antibodies,” he explained.
“If you get an infection and you get antibodies to the infection, then you’re immunocompromised.
If you don’t get antibody response to the virus, you’re at higher risk for COVID.”
Oosterholm said it’s possible that nonresponsive people are more vulnerable to the coronowscores effects, but the current research shows that the non-response is not the only risk factor for the virus.
“Non-responses are not the same as the response to infection,” he added.
Osters study is the latest of many to find evidence that the vaccination can help people shed the COVID virus.
has said that it has already given out 2 million doses of the COVE vaccine, and the World Health Organization has recommended the vaccine to the entire world.
But Osterlund said his team is still working on finding out how to get the vaccine in the U!
K., where there’s a lower vaccination rate.
The study was supported by the Ullman Foundation, the American Medical Association, and a grant from the Department of Health.
Oosterlund has published numerous papers on the vaccine and said the results were not intended to be used to diagnose or prescribe any medical treatment.
He said he and his team plan to conduct more research on the vaccines efficacy in the future.